Incyte (INCY) TD Cowen 45th Annual Healthcare Conference summary

Commercial and financial performance

• Achieved $4.2 billion in 2024 revenues, a 15% year-over-year increase, driven by strong demand for Jakafi and Opzelura across all indications.

• Opzelura revenues exceeded $500 million in 2024, with guidance for 2025 set at $630–$670 million, reflecting 24–32% growth.

• Growth in vitiligo and atopic dermatitis (AD) indications continues, supported by patient activation initiatives and increased ex-U.S. contributions, especially from Europe.

• Medicare Part D redesign provided a tailwind in 2024 and is expected to continue supporting growth in 2025.

• Patient education efforts are ongoing to maximize benefit from payment plans and therapy adherence.

Regulatory and pipeline progress

• Secured regulatory approval for Niktimvo in third-line chronic GVHD and launched for this indication.

• Filed for approval of Opzelura in pediatric atopic dermatitis, Monjuvi in relapsed/refractory follicular lymphoma, and Zynyz in squamous cell anal carcinoma, with commercialization expected in the second half of 2024.

• Significant pipeline progress positions the company for multiple readouts in 2024 and 2025, aiming to launch over 10 high-impact programs by 2030.

Clinical development highlights

• Phase III data for povorcitinib in hidradenitis suppurativa (HS) expected soon; phase II data showed a best-in-class profile with rapid symptom relief and strong HiSCR 100 rates at one year.

• Phase III studies include a more severe patient population and higher prior biologic exposure, aligning with reimbursement needs, especially in Europe.

• Disclosure of primary endpoint data (HiSCR 50 at week 12) planned initially, with broader data to be presented at a major dermatology meeting.

• NDA submission timing will depend on regulatory discussions, particularly regarding safety follow-up duration.